Global Diffuse Large B Cell Lymphoma Drug Market, Dosage, Price and Clinical Pipeline Outlook 2024 Report

“Global Diffuse Large B Cell Lymphoma Drug Market, Dosage, Price and Clinical Pipeline Outlook 2024” Report Highlights:

* Price and Dosage Analysis of Commercially Available Drugs
* Patent, Price and Dosage Analysis of Recently Approved Drugs
* Market Analysis of Diffuse Large B Cell Lymphoma
* Market Sales Opportunity till 2024
* Global Diffuse Large B Cell Lymphoma Clinical Pipeline: 84 Drugs
* Marketed Global Diffuse Large B Cell Lymphoma Clinical Insight

Download Report Sample Weblink:

https://www.kuickresearch.com/report-global-diffuse-large-b-cell-lymphoma-drug-market,-dosage,-price-and-clinical-pipeline-outlook-2024.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. Diffuse Large B Cell Lymphoma
1.1 Introduction
1.2 Classification of Diffuse Large B Cell Lymphoma

2. Molecular Events Involved in Diffuse Large B Cell Lymphoma Pathogenesis
2.1 BCL6
2.2 BCL-2
2.3 MYC Gene
2.4 P53

3. Management Approaches for Diffuse Large B Cell Lymphoma
3.1 Diagnostic Approaches
3.1.1 Bone Marrow Biopsy Method
3.1.2 Positron Emission Tomography (PET)
3.2 Therapeutic Approaches
3.3 Radiation Therapy

4. Price and Dosage Analysis of Commercially Available Drugs
4.1 Rituxan
4.2 Cyclophosphamide
4.3 Doxorubicin
4.4 Vincristine
4.5 Prednisone

5. Patent, Price and Dosage Analysis of Recently Approved Drugs
5.1 Axicabtagene Ciloleucel (Yescarta)
5.2 Ibrutinib (Imbruvica)
5.3 Hyaluronidase

6. Market Analysis of Diffuse Large B Cell Lymphoma
6.1 Introduction to Lymphoma Disease
6.1.1 Market Exploration of Hodgkin Lymphoma
6.1.2 Market Size of Non-Hodgkin Lymphoma
6.2 Market Outlook of Diffuse Large B Cell Lymphoma

7. Current Trends in Treatment of Diffuse Large B Cell Lymphoma

8. Market Dynamics of Diffuse Large B Cell lymphoma
8.1 Favorable Market Parameters
8.2 Commercialization Challenges

9. Future Perspective of Diffuse Large B Cell Lymphoma

10. Global Diffuse Large B Cell Lymphoma Clinical Pipeline by Company and Phase
10.1 Global Diffuse large B Cell Lymphoma Pipeline Overview
10.2 Research
10.3 Preclinical
10.4 Clinical
10.5 Phase-I
10.6 Phase-I/II
10.7 Phase-II
10.8 Phase-III
10.9 Registered
10.10 Preregistration

11. Marketed Global Diffuse Large B Cell Lymphoma Clinical Insight by Company
11.1 Rituximab/Hyaluronidase (MabThera SC, RITUXAN SC and Rituxan Hycela)
11.2 Rituximab Biosimilar (Novex)
11.3 Rituximab Biosimilar (Maball)

12. Competitive Landscape
12.1 AbbVie
12.2 Arrien Pharmaceuticals
12.3 Aptose Biosciences
12.4 BeiGene
12.5 Celltrion
12.6 CTI BioPharma
12.7 Erytech Pharma
12.8 Hetero Drugs
12.9 Karyopharm Therapeutics
12.10 mAbxience
12.11 PIQUR Therapeutics
12.12 Philogen S.p.A.
12.13 Roche
12.14 Seattle Genetics
12.15 TG Therapeutics

Figure 1-1: Representation of T Lymphocytes and B Lymphocytes Cases of Non-Hodgkin Lymphoma (%)
Figure 1-2: Categorization of Diffuse Large B cell Lymphoma
Figure 2-1: Role of BCL6 Gene B Cell Differentiation for the Development of Diffuse Large B cell Lymphoma
Figure 2-2: Pathogenesis of Diffuse Large B cell Lymphoma by BCL-2 Oncogene
Figure 2-3: Involvement of MYC Gene in the Proliferation of Diffuse Large B cell Lymphoma
Figure 3-1: Diagnostic Methods of Diffuse Large B cell Lymphoma
Figure 4-1: Rituxan - Patent Approval Year and Expiration Year
Figure 4-2: Rituxan - Dose Schedule in a Cycle (by Number), 2018
Figure 4-3: Rituxan - Availability in Market by Vial Concentration (mg), 2018
Figure 4-4: Global - Rituxan Intravenous Solution Price by Concentration (10mg/mL) (US$/Unit), 2018
Figure 4-5: Rituxan - Price Analysis by Concentration (US$), 2018
Figure 4-6: Rituxan - Treatment Cost Analysis for Intravenous Route of Administration (US$), 2018
Figure 4-7: Global - Rituxan Sales (US$ Billion), 2015-2017
Figure 4-8: Cyclophosphamide - Available Intravenous Powder Concentration (mg/vial), 2018
Figure 4-9: Cyclophosphamide - Available Capsule Concentration (mg/vial), 2018
Figure 4-10: Cyclophosphamide - Dosage Analysis in Initial Treatment Course (mg/kg), 2018
Figure 4-11: Cyclophosphamide - Maximum Dose in Treatment Course (mg/kg), 2018
Figure 4-12: Cyclophosphamide - Dosage Analysis for Diffuse Large B- Cell Lymphoma (mg/m2/Day), 2018
Figure 4-13: Cyclophosphamide - Intravenous Powder Price Analysis by Concentration (mg), 2018
Figure 4-14: Cyclophosphamide - Capsule Price Analysis by Concentration (mg), 2018
Figure 4-15: Doxorubicin - Available Intravenous Powder Concentration (mg), 2018
Figure 4-16: Doxorubicin - Availability in Market by Vial Quantity (2mg/ml), 2018
Figure 4-17: Doxorubicin - Initial Dosage (mg/m2/Dose)
Figure 4-18: Doxorubicin - Maximum Dosage (mg/m2/Dose)
Figure 4-19: Doxorubicin - Duration of Treatment Cycle (Number of Days)
Figure 4-20: Doxorubicin - Intravenous Powder Price Analysis by Concentration (US$), 2018
Figure 4-21: Doxorubicin - Intravenous Solution Price Analysis by Concentration (US$), 2018
Figure 4-22: Vincristine - Dosage Analysis (mg/ml/Week)
Figure 4-23: Vincristine - Availability in Market by Vial Quantity (ml), 2018
Figure 4-24: Vincristine - Intravenous Solution Price Analysis by Concentration (US$), 2018
Figure 4-25: Prednisone - Available Oral Solution by Concentration (ml), 2018
Figure 4-26: Prednisone - Available Oral Tablet by Concentrations (mg), 2018
Figure 4-27: Prednisone - Oral Solution Price Analysis by Concentration (US$), 2018
Figure 4-28: Prednisone - Oral Tablet Cost Price Analysis (US$/100 Tablets), 2018
Figure 5-1: Yescarta - Patent Approval Year in US and Estimate Treatment Cost (US$)
Figure 5-2: Information of Yescarta Drug among the Population (%)
Figure 5-3: Imbruvica - US Patent Approval Year and Patent Expiration Year
Figure 5-4: Imbruvica - 140mg Capsule Price Analysis (US$/Packet), 2018
Figure 5-5: Imbruvica - Treatment Cost Analysis (US$), 2018
Figure 5-6: Imbruvica - Clinical Efficacy by Survival Rate and Survival Response (%), 2018
Figure 5-7: Imbruvica - Global Sales (US$ Billion), 2015 - 2017
Figure 5-8: Rituxan Hycela - Availability by Concentration (ml), 2018
Figure 5-9: Rituxan Hycela - Cell Units in Vial (by Number), 2018
Figure 5-10: Rituxan Hycela - Dosage in CHOP Therapy (mg/Cell Units), 2018
Figure 5-11: Rituxan Hycela - Price Analysis by Concentration (US$/Unit), 2018
Figure 5-12: Rituxan Hycela - Vial Price Analysis (US$), 2018
Figure 6-1: Global - Estimated Number of All New Annual Cancer Cases (%), 2018
Figure 6-2: Estimated New Annual Cases of Blood Cancers, 2018 (%)
Figure 6-3: Distribution of Types of Lymphoma (%)
Figure 6-4: Global - Hodgkin Lymphoma Market Opportunity (US$ Billion), 2017-2024
Figure 6-5: Global- Non-Hodgkin Lymphoma Market Growth Estimation (US$ Billion), 2017-2024
Figure 6-6: Classification of Subtypes of Non-Hodgkin Lymphoma Market (%)
Figure 6-7: Global - Patients Affected by Issues Before, During and After the Treatment (%), 2016
Figure 6-8: Barriers to Adequate Treatment Approach of Diffuse Large B cell Lymphoma (%), 2016
Figure 8-1: Favorable Factors for the Growth of Diffuse Large B cell Lymphoma Market
Figure 8-2: Challenges to the Growth of Diffuse Large B cell Lymphoma Market
Figure 10-1: Global Diffuse Large B Cell Lymphoma Clinical Pipeline by Phase (%), 2018 till 2024
Figure 10-2: Global Diffuse Large B Cell Lymphoma Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 10-3: Global Diffuse Large B Cell Lymphoma Clinical Pipeline by Phase (%),2018 till 2024
Figure 10-4: Global Diffuse Large B Cell Lymphoma Clinical Pipeline by Phase (Number), 2018 till 2024






Table 3-1: Diagnostic Positron Emission Tomography Scan by Histology
Table 3-2: Standard Regimen of R-CHOP Chemotherapy plus Monoclonal Antibody for 6 Cycles
Table 5-1: Response Rate of Recipients who Received Yescarta Drug in Clinical Trials (%)
Table 5-2: Cost Effective Analysis of Imbruvica Drug
Table 5-3: Response Effective Analysis of Rituxan Hycela Injection in Clinical Trials
Table 9-1: Ongoing PD-1 Inhibitors Clinical Trials Related with Diffuse Large B cell Lymphoma

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.